237 related articles for article (PubMed ID: 31227646)
1. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E; Tarantelli C; Spriano F; Guidetti F; Sartori G; Bordone R; Arribas AJ; Cascione L; Bigioni M; Merlino G; Fiascarelli A; Bressan A; Adjeiwaa Mensah A; Golino G; Lucchini R; Bernasconi E; Rossi D; Zucca E; Stussi G; Stathis A; Boyd RS; Dusek RL; Bisht A; Attanasio N; Rohlff C; Pellacani A; Binaschi M; Bertoni F
Haematologica; 2020 Nov; 105(11):2584-2591. PubMed ID: 33131247
[TBL] [Abstract][Full Text] [Related]
3. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
4. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
6. PE-Cy5.5 conjugates bind to the cells expressing mouse DEC205/CD205.
Park CG; Rodriguez A; Steinman RM
J Immunol Methods; 2012 Oct; 384(1-2):184-90. PubMed ID: 22841832
[TBL] [Abstract][Full Text] [Related]
7. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
8. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
9. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
10. An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities.
Nicolazzi C; Caron A; Tellier A; Trombe M; Pinkas J; Payne G; Carrez C; Guérif S; Maguin M; Baffa R; Fassan M; Adam J; Mangatal-Wade L; Blanc V
Mol Cancer Ther; 2020 Aug; 19(8):1660-1669. PubMed ID: 32451330
[TBL] [Abstract][Full Text] [Related]
11. Identification of pro-inflammatory CD205
Yong L; Li M; Gao Y; Deng Y; Liu W; Huang D; Ren C; Liu M; Shen J; Hou X
Sci Rep; 2017 Apr; 7():46765. PubMed ID: 28436459
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a monoclonal antibody against porcine CD205.
Flores-Mendoza L; Velazquez C; Bray J; Njongmeta L; Mwangi W; Hernández J
Vet Immunol Immunopathol; 2012 Mar; 146(1):74-80. PubMed ID: 22348805
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
[TBL] [Abstract][Full Text] [Related]
15. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
16. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self.
Shrimpton RE; Butler M; Morel AS; Eren E; Hue SS; Ritter MA
Mol Immunol; 2009 Mar; 46(6):1229-39. PubMed ID: 19135256
[TBL] [Abstract][Full Text] [Related]
17. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
19. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
20. CD205
Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
